Oncolytics Biotech Inc. (ONCY)
Stock Price:
$1.90 USD
-0.01 (-0.52%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
50.08M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-33.12M |
| Shares Out |
40.49M |
| EPS (ttm) |
-0.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$1.90 |
| Previous Close |
$1.91 |
| Change ($) |
-0.01 |
| Change (%) |
-0.52% |
| Day's Open |
1.91 |
| Day's Range |
1.87 - 1.93 |
| Day's Volume |
387,633 |
| 52-Week Range |
0.35 - 6.02 |
More Stats
| Market Cap |
50.08M |
| Enterprise Value |
36.44M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
40.49M |
| Float |
38.64M |
| EPS (basic) |
-1.5 |
| EPS (diluted) |
-0.83 |
| FCF / Share |
-0.90 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.92M |
| Short Ratio |
1.25 |
| Short % of Float |
4.81% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.36 |
| Revenue |
n/a |
| Operating Income |
-20.69M |
| Net Income |
-33.12M |
| Free Cash Flow |
-19.92M |
| Net Cash |
13.64M |
| Net Cash / Share |
0.52 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-52.37% |
| ROE |
-190.75% |
| ROIC |
779.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.99*
(267.89% upside)
Low
4.31
Current: 1.90
High
9.00
Target: 6.99
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -20.69 | -16.66 | -15.61 | -15.29 | -13.92 |
| Net Income | -33.12 | -17.04 | -15.62 | -15.14 | -13.72 |
| Shares Outstanding | 22.14 | 16.02 | 13.94 | 12.62 | 11.85 |
| Earnings Per Share | -1.50 | -1.06 | -1.12 | -1.20 | -1.14 |
| Operating Cash Flow | -19.91 | -11.92 | -14.89 | -12.48 | -15.03 |
| Capital Expenditures | -0.01 | -0.11 | -0.11 | -0.02 | -0.11 |
| Free Cash Flow | -19.92 | -12.03 | -15.00 | -12.50 | -15.14 |
| Cash & Equivalents | 14.15 | 13.70 | 11.84 | 14.12 | 0.00 |
| Total Debt | 0.51 | - | - | - | - |
| Net Cash / Debt | 13.64 | 13.70 | 11.84 | 14.12 | 0.00 |
| Assets | 19.66 | 14.87 | 18.15 | 14.76 | - |
| Liabilities | 19.77 | 8.67 | 9.87 | 4.07 | - |
| Book Value | -0.11 | 6.20 | 8.28 | 10.69 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Oncolytics Biotech Inc. |
| Country |
Canada |
| CEO |
Matthew C. Coffey |
Stock Information
| Ticker Symbol |
ONCY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ONCY |
| IPO Date |
November 8, 1999 |
Description
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.